Hindustan Bio Sciences Limited reported a standalone net loss of ₹11.29 lakh for the first quarter ended June 30, 2026 (Q1FY27), marking a significant deterioration from the net profit of ₹1.40 lakh recorded in the corresponding period of FY26. The company’s revenue from operations dropped to zero, compared to ₹32.19 lakh in Q1FY25, signaling a complete halt in trading activities during the quarter. Total expenses stood at ₹11.29 lakh, driven primarily by employee benefit expenses of ₹5.72 lakh and other expenses of ₹5.56 lakh.

The Board of Directors approved the unaudited standalone financial results on July 31, 2026, in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, Vasg & Associates, who issued an unmodified opinion. The company operates in a single reportable segment: Trading of Pharmaceuticals.

Financial Performance

The financial data reveals a sharp contraction in top-line activity while fixed costs persisted. In Q1FY27, revenue from operations was nil, and other income was also zero. This contrasts with Q1FY25, where the company generated ₹32.19 lakh from operations and ₹1.31 lakh from other income.

Employee benefit expenses increased slightly to ₹5.72 lakh from ₹4.40 lakh in the previous year’s quarter. Purchases of stock-in-trade, which accounted for ₹21.19 lakh in Q1FY25, dropped to zero in the current quarter, aligning with the absence of operational revenue. Finance costs and selling expenses were negligible, recorded at ₹0.00 lakh and ₹0.01 lakh respectively.

What the Numbers Show

The most critical observation is the complete cessation of revenue generation alongside persistent operational expenditures. While the company avoided variable costs such as purchases of stock-in-trade and material consumption, it continued to incur fixed overheads, particularly employee benefits and other administrative expenses. This divergence between zero revenue and sustained expenses directly caused the swing from a profit position in Q1FY25 to a loss in Q1FY27. The lack of any other income further exacerbated the bottom-line pressure, indicating no offsetting gains from investments or interest during the period.

Corporate Governance Updates

In addition to approving the financial results, the Board fixed the date for the 34th Annual General Meeting (AGM) as Wednesday, September 30, 2026, at 10:00 A.M. The meeting will be held at the company’s registered office in Hyderabad. Mr. VBSS Prasad, a practicing Company Secretary, was appointed as the scrutinizer to oversee the remote e-voting process and voting at the venue, ensuring transparency in shareholder participation. The notice convening the AGM, along with the Directors’ Report and Corporate Governance Report for FY26, was also approved.

hindustan bio sciences has published its audited standalone financial results for the fourth quarter and financial year ended March 31, 2026. The company released the financial statements pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The results were published in Hitech Edition (English) on June 2, 2026, and in The Praja Palana (Telugu) on June 1, 2026. The audited financial results and statements are accessible on the websites of BSE Limited and the company.

Publication Details

The company intimated the stock exchange regarding the publication of these results. The intimation, signed by Managing Director Venkata Rama Mohan Raju Jampana, confirmed the dissemination of the financial data.

Accessing the Results

The audited standalone financial results and financial statements can be accessed on the BSE Limited website and the official website of Hindustan Bio Sciences Limited. A specific QR code has also been provided for direct access to the financial results document.